Orlistat and Wegovy are weight-management treatment options, but they differ in regulatory access, treatment routines and clinical evidence. Orlistat is a gastrointestinal lipase inhibitor offered in the United States as OTC Alli 60 mg and prescription 120 mg products. Wegovy contains semaglutide, a GLP-1 receptor agonist, and has U.S. prescription labeling for weight management in eligible populations as well as other product-specific indications. A person comparing them must evaluate exact labeling rather than assume they are equivalent simply because both are discussed in obesity care.
The Wegovy name now encompasses injectable and oral tablet presentations in the United States, with different administration requirements. This page compares Wegovy as an obesity-branded treatment portfolio against orlistat. The narrower questions of the Wegovy pill compared with orlistat and semaglutide ingredient compared with orlistat have their own guides.
OrliLab provides independently edited educational comparisons and may receive disclosed affiliate compensation. We do not prescribe or dispense either medicine, verify inventory or determine personal eligibility. A treatment decision should consider the approved indication, medical history, patient preference, observed study populations and realistic access rather than an advertised promise of a particular amount of weight loss.
This named-brand comparison centers on whether a U.S. consumer is evaluating an OTC or prescription orlistat product or a prescription Wegovy product for a labeled weight-management setting. Wegovy has more than one formulation, so “injection versus capsule” is no longer a complete description of the available formats.
The table separates the most important decision dimensions without turning treatment labels into a recommendation or assuming that an advertised pharmacy price represents current inventory.
| Decision factor | Orlistat | Wegovy |
|---|---|---|
| Ingredient/class | Orlistat / gastrointestinal lipase inhibitor | Semaglutide / GLP-1 receptor agonist |
| Primary comparison | OTC 60 mg or prescription 120 mg | Prescription obesity-branded products |
| Formats | Oral capsules | Weekly injection (including Wegovy HD) or daily oral tablets; distinct instructions |
| Mechanism | Reduces dietary fat absorption | Appetite/metabolic pathways |
| Medical access | OTC label rules or prescriber for 120 mg | Prescriber evaluation required |
| Typical counseling | Meals, GI effects, vitamins and interactions | GI tolerance, titration, administration and boxed warning |
Wegovy should be compared to orlistat in the context of its own weight-management indications, not through Ozempic’s diabetes-focused brand positioning. Wegovy injection has additional product-specific indications, including treatment of certain adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis (F2–F3) under accelerated approval. Both the injection and tablets carry cardiovascular risk-reduction indications for qualifying adults, while the tablets have their own adult weight-management label. The exact presentation and approved population therefore matter. Obesity eligibility cannot be decided by a web comparison alone.
For a diabetes-brand contrast, orlistat versus Ozempic is the appropriate destination. Orlistat’s OTC and prescription indications likewise differ, making the orlistat OTC status guide relevant before assuming which option can be purchased without a prescription.
Wegovy has brand-specific clinical trials measuring weight change with lifestyle intervention, and prescription orlistat has its own established trial literature. Differences in baseline body weight, diabetes status, follow-up length, study design and missing-data methods make direct comparisons across unrelated studies unreliable.
Clinical conversations should distinguish average trial responses from individual expectations and should address treatment persistence and weight regain after stopping therapy. The orlistat efficacy overview focuses on the orlistat evidence rather than attempting a fabricated head-to-head outcome.
Orlistat capsules are taken in a meal-linked regimen according to their specific labeling. Wegovy injection uses a once-weekly subcutaneous routine; the U.S. portfolio also includes Wegovy HD 7.2 mg for weight reduction in certain adults. Wegovy tablets require morning administration on an empty stomach with no more than four ounces of plain water, followed by at least 30 minutes before eating, drinking or taking other oral medicines. Product-specific titration and missed-dose instructions require the exact prescription label.
An aversion to needles may make an oral product seem appealing, but it does not make an oral GLP-1 therapy OTC or free of administration restrictions. The Wegovy tablet access page treats the oral product as a separate pharmacy and administration decision.
Orlistat can cause oily gastrointestinal effects and affect fat-soluble vitamin absorption, while its prescription and OTC labeling also address contraindications, interacting medicines and rare kidney injury. Diet composition influences tolerability but is not a substitute for following approved instructions.
Wegovy carries the semaglutide boxed warning concerning thyroid C-cell tumors in rodents and important contraindications related to medullary thyroid carcinoma and MEN2. Its label also addresses pancreatitis, gallbladder issues, severe GI effects and volume depletion. Compare orlistat safety considerations without assuming the GLP-1 risk profile applies identically.
Alli 60 mg can be purchased according to its OTC label, while prescription orlistat 120 mg and Wegovy require authorized prescriber involvement. Insurance requirements for weight-management medicines can vary significantly, and an apparent lower retail price may not reflect the patient’s actual plan benefit or access to a particular product.
The Wegovy prescription buying guide addresses lawful access, while insurance coverage checks explains questions to ask about formularies and benefit exclusions. Neither route guarantees approval, reimbursement or pharmacy supply.
Consider the demands of storing and using the prescribed formulation, attending follow-up appointments, tolerating adverse effects and maintaining nutrition. Orlistat users should understand the consequences of dietary-fat intake and vitamin considerations; Wegovy users should understand their product’s titration and administration expectations.
Long-term weight management also requires appropriate dietary and activity support, and stopping a medicine may affect treatment outcomes. Neither product eliminates the need for clinical review when underlying medical conditions or interacting medicines are present.
Wegovy injection has a weight-management indication for adults and adolescents aged 12 years or older with obesity, whereas Wegovy tablets have adult weight-management and cardiovascular risk-reduction indications. Wegovy HD is a high-dose injectable option for certain adults, not a tablet or a pediatric label. OTC Alli 60 mg has its own adult-use Drug Facts requirement (age 18 or older), while prescription orlistat 120 mg has different professional labeling.
For families discussing adolescent care, the prescriber should verify the exact labeled indication, age restrictions, monitoring obligations and appropriateness of treatment. This comparison does not replace that assessment.
Make the comparison using actual product names and formulations: OTC capsule packs, a 120 mg prescription supply, Wegovy injection supply or Wegovy tablets. Include prescription services, pharmacy fees, relevant supplies and insurance rules rather than comparing disconnected headline advertisements.
For orlistat, price and pack-size factors offers an evergreen breakdown. For Wegovy, verify the current authorized pharmacy channel and total charge because price and availability can change.
Ask whether the intended indication is an appropriate match, how evidence applies with or without type 2 diabetes, which warnings merit special consideration, and how changes in treatment would be supervised. Diabetes medicines, gastrointestinal conditions, gallbladder history and planned pregnancy can change the clinical discussion.
Never assume that moving from a nonprescription product to Wegovy is an automatic escalation, or that a medicine can be switched without supervision. A licensed clinician must evaluate interactions and individual health risks.
If the question is which weight-management brand is suitable to discuss with a clinician, this page provides the broad comparison. If the question is how Wegovy tablets differ specifically from orlistat capsules, use the oral formulation comparison and verify the current branded label.
For competing prescription obesity products, Zepbound versus orlistat addresses a separate mechanism and product. For retail access to orlistat itself, buying orlistat in the U.S. covers the OTC/Rx split.
No. Wegovy contains semaglutide, while orlistat is a gastrointestinal lipase inhibitor.
No. Wegovy is a prescription medicine regardless of formulation.
Yes. U.S. Wegovy labeling includes prescription tablets for adults alongside injection products. The tablet formulation requires a specific morning fasting routine and is not administered like a meal-associated orlistat capsule.
No. Alli 60 mg is an OTC orlistat product, while Wegovy is a prescription semaglutide brand.
Wegovy and orlistat studies provide useful efficacy evidence, but their populations, follow-up periods and analysis methods differ. Separate trial averages do not establish an individualized outcome or a direct head-to-head result.
No. Wegovy tablets are taken on an empty stomach in the morning with limited plain water and a 30-minute waiting period. Orlistat instructions relate to main meals and dietary fat.
No. Orlistat commonly causes fatty stool and bowel urgency and can affect vitamin absorption. Wegovy has different gastrointestinal effects and a boxed warning about thyroid C-cell tumors observed in rodents.
No. Coverage depends on the individual policy, indication, formulary and any authorization requirements.
Medication changes should be discussed with a qualified prescriber who can evaluate risks, other medicines and monitoring.
Both contain semaglutide, but they are distinct brands with different approved labeling and product-specific instructions.